|
|
|
|
|
| Dias,R.S.; Carmo,L.S.; Heneine,L.G.D.; Rocha,P.H.; Barbosa,C.F.; Rodrigues,R.J.; Linardi,V.R.. |
| Acute toxicity test (LD-50) using toxic shock syndrome toxin (TSST-1) was tested in BALB/c, C57BL/6 and Swiss mice. Animals (n = 10) were intraperitoneally injected with TSST-1 (0.01-10.0µg/mouse) followed 4h later by potentiating dose of lipopolysaccharide (75.0µg of LPS - E. coli O111:B4) and cumulative mortality was recorded over 72h. Control animals received either TSST-1 or LPS alone. The data were submitted to qui-Square test and acute toxicity test was calculated by probit analysis (confidence limits expressed as µg toxin/kg). BALB/c mice was the most sensitive (20.0µg/kg, 95% confidence limits: 9.0-92.0) followed by C57BL/6 (38.5µg/kg, 95% confidence limits: 9.11- 401.6). Data from Swiss mice was not conclusive, indicating only low sensitivity.... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Mice; TSST-1; Acute toxicity (LD-50); Staphylococcus. |
| Ano: 2009 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-09352009000100024 |
| |
|
|
| Barbosa,C.F.; Okuda,E.S.; Chung,M.C.; Ferreira,E.I.; Cicarelli,R.M.B.. |
| No fully effective treatment has been developed since the discovery of Chagas' disease by Carlos Chagas in 1909. Since drug-resistant Trypanosoma cruzi strains are occurring and the current therapy is effectiveness in the acute phase but with various adverse side effects, more studies are needed to characterize the susceptibility of T. cruzi to new drugs. Many natural and/or synthetic substances showing trypanocidal activity have been used, even though they are not likely to be turned into clinically approved drugs. Originally, drug screening was performed using natural products, with only limited knowledge of the molecular mechanism involved in the development of diseases. Trans-splicing, which is unusual RNA processing reaction and occurs in nematodes... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Trypanosoma cruzi; Trans-splicing; Trypanocidal drugs; Permeable cells; RNA processing; Hydroxymethylnitrofurazone. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000100005 |
| |
|
|
|
